Clinical trial
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced…
NCT00014495 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00014495 |
|---|---|
| Title | Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer |
| Official title | Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Biological, Drug, Radiation |
| Interventions | filgrastim, cytarabine, bismuth Bi213 monoclonal antibody M195 |
| Enrollment | 32 |
| Start date | Nov 1, 2000 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 22, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: